Subject(s)
Diverticulum, Esophageal/surgery , Esophageal Motility Disorders/surgery , Esophageal Sphincter, Lower/surgery , Esophagoscopy , Myotomy , Aged , Diverticulum, Esophageal/complications , Diverticulum, Esophageal/physiopathology , Esophageal Motility Disorders/complications , Esophageal Motility Disorders/physiopathology , Esophageal Sphincter, Lower/physiopathology , Female , Humans , ManometryABSTRACT
BACKGROUND: Endoscopic resection of lesions involving the appendiceal orifice remains a challenge. We aimed to report outcomes with the full-thickness resection device (FTRD) for the resection of appendiceal lesions and identify factors associated with the occurrence of appendicitis. METHODS: This was a retrospective study at 18 tertiary-care centers (USA 12, Canada 1, Europe 5) between November 2016 and August 2020. Consecutive patients who underwent resection of an appendiceal orifice lesion using the FTRD were included. The primary outcome was the rate of R0 resection in neoplastic lesions, defined as negative lateral and deep margins on post-resection histologic evaluation. Secondary outcomes included the rates of: technical success (en bloc resection), clinical success (technical success without need for further surgical intervention), post-resection appendicitis, and polyp recurrence. RESULTS: 66 patients (32 women; mean age 64) underwent resection of colonic lesions involving the appendiceal orifice (mean [standard deviation] size, 14.5 (6.2) mm), with 40 (61â%) being deep, extending into the appendiceal lumen. Technical success was achieved in 59/66 patients (89â%), of which, 56 were found to be neoplastic lesions on post-resection pathology. Clinical success was achieved in 53/66 (80â%). R0 resection was achieved in 52/56 (93â%). Of the 58 patients in whom EFTR was completed who had no prior history of appendectomy, appendicitis was reported in 10 (17â%), with six (60â%) requiring surgical appendectomy. Follow-up colonoscopy was completed in 41 patients, with evidence of recurrence in five (12â%). CONCLUSIONS: The FTRD is a promising non-surgical alternative for resecting appendiceal lesions, but appendicitis occurs in 1/6 cases.
Subject(s)
Appendix , Endoscopic Mucosal Resection , Colonoscopy , Female , Humans , Middle Aged , Retrospective Studies , Treatment OutcomeABSTRACT
Video 1Percutaneous transcystic cholangioscopy-assisted rendezvous ERCP in a hostile abdomen.
ABSTRACT
BACKGROUND: Endoscopic ultrasound-directed transgastric endoscopic retrograde cholangiopancreatography (ERCP; EDGE) is an alternative to enteroscopy- and laparoscopy-assisted ERCP in patients with Roux-en-Y gastric bypass anatomy. Although short-term results are promising, the long-term outcomes are not known. The aims of this study were: (1) to determine the rates of long-term adverse events after EDGE, with a focus on rates of persistent gastrogastric or jejunogastric fistula; (2) to identify predictors of persistent fistula; (3) to assess the outcomes of endoscopic closure when persistent fistula is encountered. METHODS: This was a multicenter retrospective study involving 13 centers between February 2015 and March 2019.âAdverse events were defined according to the ASGE lexicon. Persistent fistula was defined as an upper gastrointestinal series or esophagogastroduodenoscopy showing evidence of fistula. RESULTS: 178 patients (mean age 58 years, 79â% women) underwent EDGE. Technical success was achieved in 98â% of cases (175/178), with a mean procedure time of 92 minutes. Periprocedural adverse events occurred in 28 patients (15.7â%; mild 10.1â%, moderate 3.4â%, severe 2.2â%). The four severe adverse events were managed laparoscopically. Persistent fistula was diagnosed in 10â% of those sent for objective testing (9/90). Following identification of a fistula, 5â/9 patients underwent endoscopic closure procedures, which were successful in all cases. CONCLUSIONS: The EDGE procedure is associated with high clinical success rates and an acceptable risk profile. Persistent fistulas after lumen-apposing stent removal are uncommon, but objective testing is recommended to identify their presence. When persistent fistulas are identified, endoscopic treatment is warranted, and should be successful in closing the fistula.
Subject(s)
Cholangiopancreatography, Endoscopic Retrograde , Gastric Bypass , Endoscopy, Gastrointestinal , Endosonography , Female , Gastric Bypass/adverse effects , Humans , Male , Middle Aged , Retrospective StudiesSubject(s)
Esophageal Achalasia , Heller Myotomy , Myotomy , Esophageal Achalasia/surgery , Humans , Japan , Prospective StudiesABSTRACT
The name of author Vivek Kumbhari was misspelled in the original article.
ABSTRACT
INTRODUCTION AND AIM: Endoscopic sleeve gastroplasty (ESG) is a procedure in which endoscopically placed sutures involute the stomach and promote weight loss. There is limited data on the durability of these sutures. PATIENTS AND METHODS: This was a single center series of 5 patients who underwent ESG performed by a single endoscopist. Patients underwent repeat endoscopy for different clinical indications. RESULTS: ESGs were successfully reversed at 3 weeks and 1 month following index ESG without significant fibrosis or scaring. At 8 and 14 months, a few sutures had dehisced though there were extensive areas of fibrosis. By 2 years, most of the sutures had dehisced; however, the gastric volume remained reduced. CONCLUSION: This case series offers an intriguing evaluation of the anatomical changes induced by ESG.
Subject(s)
Gastroplasty , Obesity, Morbid , Endoscopy , Gastroplasty/adverse effects , Humans , Obesity/surgery , Obesity, Morbid/surgery , Stomach/surgery , Sutures , Treatment OutcomeABSTRACT
Background and study aims Indications for accessing the duodenum, and/or excluded stomach in Roux-en-Y gastric bypass (RYGB) patients extend beyond diagnosis and treatment of pancreaticobiliary maladies. Given the high technical and clinical success of EUS-directed transgastric ERCP (EDGE) in RYGB anatomy, we adopted this transgastric (anterograde) approach to evaluate and treat luminal and extraluminal pathology in and around the excluded gut in RYGB patients. EUS-directed transgastric intervention ("EDGI"), other than ERCP, is the terminology we have chosen to describe this heterogenous group of transgastric diagnostic and/or interventional endoscopic procedures (transgastric interventions) performed via a lumen-apposing mental stent (LAMS) in select patients with RYGB. Patients and methods A multicenter (nâ=â4), retrospective study of RYGB patients with suspected luminal or extraluminal pathology, in or around the duodenum and/or excluded stomach, underwent EDGI using LAMS between December 2015 and January 2019. Results A total of 14 patients (78.6â% women; mean age, 55.7â+â12.4 years) underwent EDGI via LAMS. Technical and clinical success rates of EDGI were 100â%. The most common transgastric interventions were diagnostic EUS of extraluminal pathology (nâ=â6, 42.7â%) and endoscopic biopsy of gastroduodenal luminal abnormalities (nâ=â5, 35.7â%). Two moderate-severity adverse events due to LAMS maldeployment occurred during EUS-JG creation (14.3â%), and each instance was successfully rescued with a bridging stent. Conclusions A variety of gastroduodenal luminal and extraluminal disorders in RYGB patients can be effectively diagnosed and managed using EDGI via LAMS.
Subject(s)
Cholecystitis, Acute , Drainage , Duodenostomy/methods , Duodenum/surgery , Endoscopy, Gastrointestinal , Endosonography/methods , Gallbladder , Cholecystitis, Acute/diagnosis , Cholecystitis, Acute/etiology , Cholecystitis, Acute/surgery , Cholecystolithiasis/complications , Cystic Duct/surgery , Drainage/instrumentation , Drainage/methods , Endoscopy, Gastrointestinal/methods , Female , Gallbladder/diagnostic imaging , Gallbladder/surgery , Humans , Middle Aged , Stents , Surgery, Computer-Assisted/methods , Treatment OutcomeABSTRACT
BACKGROUND: Intravenous contrast-enhanced imaging is invaluable in diagnosing pathology following liver transplantation. Given the potential risk of contrast nephropathy associated with iodinated computed tomography contrast, alternate contrast modalities need to be examined, especially in the setting of renal insufficiency. The purpose of this study was to examine the renal safety of MRI with gadolinium following liver transplantation. METHODS: The study involved a retrospective analysis of 549 cases of abdominal MRI with low-dose gadobenate dimeglumine in liver transplant recipients at a single center. For each case, serum creatinine values before and after the MRI were compared. In addition, cases were analyzed for the development of nephrogenic systemic fibrosis. RESULTS: Pre-MRI creatinine values ranged from 0.32 to 6.57 mg/dL (median, 1.28 g/dL), with 191 cases having values ≥1.5 mg/dL (median, 1.86 g/dL). A comparison of the pre- and post-MRI creatinine values showed no significant difference, including those patients with pre-MRI values ≥1.5 mg/dL (mean change of -0.04 [95% confidence interval, -0.07 to -0.01; P = 0.004]). No cases of nephrogenic systemic fibrosis were noted. CONCLUSIONS: Our findings suggest that, irrespective of baseline renal function, MRI with gadobenate dimeglumine is a nonnephrotoxic imaging modality in liver transplant recipients. Importantly, this intravenous contrast-enhanced imaging modality can be considered in those posttransplant patients who have a contraindication to computed tomography contrast due to renal insufficiency.
Subject(s)
Acute Kidney Injury/chemically induced , Contrast Media/adverse effects , Liver Transplantation/adverse effects , Magnetic Resonance Imaging/adverse effects , Meglumine/analogs & derivatives , Nephrogenic Fibrosing Dermopathy/chemically induced , Organometallic Compounds/adverse effects , Postoperative Complications/diagnostic imaging , Acute Kidney Injury/diagnosis , Acute Kidney Injury/epidemiology , Administration, Intravenous , Adult , Aged , Biomarkers/blood , Contrast Media/administration & dosage , Creatinine/blood , Female , Georgia/epidemiology , Humans , Incidence , Male , Meglumine/administration & dosage , Meglumine/adverse effects , Middle Aged , Nephrogenic Fibrosing Dermopathy/diagnosis , Nephrogenic Fibrosing Dermopathy/epidemiology , Organometallic Compounds/administration & dosage , Postoperative Complications/epidemiology , Renal Insufficiency/diagnosis , Renal Insufficiency/epidemiology , Retrospective Studies , Risk Assessment , Risk Factors , Time FactorsABSTRACT
BACKGROUND: Weight regain (WR) after gastric bypass is thought to be multifactorial in etiology with behavioral, neurohormonal, and anatomic features playing a role. A significant proportion of patients complain of dysphagia after Roux-en-Y gastric bypass (RYGB) and may have difficulty tolerating solid foods. Our observations suggest that this subgroup of patients compensate for esophageal symptoms by increasing their intake of calorie-dense liquid and soft foods, which can precipitate WR. OBJECTIVES: We hypothesize that dysphagia predisposes to greater WR than seen in individuals without swallowing symptoms. SETTING: Single tertiary care referral center. METHODS: This was a matched-cohort study analysis of prospectively collected data on RYGB patients. All individuals who underwent high-resolution manometry after RYGB were enrolled. Controls were identified via a retrospective analysis of a prospective institutional database. Patients who developed dysphagia were matched with controls, from a subset of 450 eligible controls. Each patient with dysphagia was matched with 4 control patients based on age, body mass index, and time since surgery. WR was defined as an increase of ≥15% from nadir. Χ2 and t test (or Wilcoxon rank sum, if applicable) were used for bivariable analysis. Multiple logistic and linear regression were used for multivariable calculations. RESULTS: Forty-nine patients with dysphagia were included. After matching, there were 196 RYGB controls that did not have swallowing or esophageal symptoms. Controls had similar baseline demographic characteristics and initial weight loss compared with dysphagia cases. WR was common in both groups; however, total WR in those with dysphagia was greater than controls (15.7 versus 11.4 kg, respectively; P = .02). In addition, percent WR in those with dysphagia exceeded that seen in controls (mean 37% versus 25%, P = .003), and more individuals regained 15% of nadir weight (55% of dysphagia cases versus 38% of controls, P = .03) when adjusting for baseline body mass index, age at surgery, and race. Dietary histories suggested that, among those with dysphagia, patients with partial or complete conversion to soft or liquid calories had greater WR than those who adhered to the solid food diet. CONCLUSIONS: Dysphagia is a risk factor for WR post-RYGB. This is likely due to increased intake of soft or liquid foods that are tolerable in these patients but lead to a positive energy balance and accelerated WR. More than half of patients with dysphagia after RYGB regain significant weight. Screening for and aggressively managing dysphagia in patients before or after RYGB may be warranted to prevent significant WR.
Subject(s)
Deglutition Disorders/etiology , Gastric Bypass/methods , Postoperative Complications/etiology , Weight Gain , Anastomosis, Roux-en-Y , Case-Control Studies , Female , Humans , Longitudinal Studies , Male , Manometry , Middle Aged , Retrospective Studies , Risk FactorsABSTRACT
AIM: ColoWrap is an external abdominal compression device applied during colonoscopy to reduce looping and procedure time. It is unclear if a shorter procedure duration or increased abdominal pressure impacts polyp detection. We determined if use of ColoWrap affected adenoma detection rate (ADR) or detection of sessile serrated polyps (SSP) compared to sham. MATERIALS AND METHODS: At a single center, participants aged 40-80 were randomized to have ColoWrap or a sham device applied to the lower abdomen. Baseline characteristics, procedural factors, location of polyps, ADR and SSP detection rate (SSPDR) were compared between the groups. Multivariable logistic regression was performed to assess whether ColoWrap was associated with detection of adenomas and SSP. RESULTS: Of 350 participants, 175 were assigned to each arm. Overall, there were no significant differences in ADR (43% vs 40%, p = 0.52) or SSPDR (8% vs 6%, p = 0.53) between ColoWrap and sham. In sub-group analysis, there were increased odds of adenoma detection with ColoWrap in women (OR: 2.32, 95%CI: 1.21, 4.46), participants > 60 years (OR: 2.95, 95%CI: 1.43, 6.07) and those with a BMI 30-40 (OR: 3.50, 95%CI: 1.00, 12.23). Use of ColoWrap also increased ADR in the left colon (splenic flexure to rectum) (29% vs 22%; p = 0.03) and increased SSPDR in the cecum/ascending colon (6% vs 2%; p = 0.02) compared to sham. CONCLUSION: Use of ColoWrap during colonoscopy did not negatively impact ADR or SSPDR, and there was an apparent improvement in polyp detection in certain colon locations and patient sub-groups. These results should be interpreted with caution due to the small sample size.
ABSTRACT
OBJECTIVES: While topical corticosteroids are first-line therapy for eosinophilic esophagitis (EoE), the data regarding long-term effectiveness are lacking. We aimed to determine long-term histologic and endoscopic outcomes of maintenance therapy in EoE steroid responders. METHODS: We performed a retrospective study of adults with EoE at UNC Hospitals who had initial histologic response (<15 eos/hpf) after 8 weeks of topical steroids, and maintained on therapy. Endoscopic and the histologic data were recorded at baseline and follow-up endoscopies. Multivariable logistic regression was performed to assess loss of treatment response by steroid dose at recurrence, and Kaplan-Meier analysis to calculate durability of disease remission. RESULTS: Of 55 EoE patients with initial response to swallowed/topical fluticasone or budesonide over a median 11.7 months, 33 had at least two follow-up EGDs. Of these patients, 61% had histologic loss of response and worse endoscopic findings. There was no difference in baseline steroid dose (P=0.55) between the groups, but those maintained on their initial dose had lower odds (OR: 0.10; 95% CI: 0.01, 0.90) of loss of response compared to those who had subsequent dose reduction. On survival analysis, 50% had loss of response to steroids by 18.5 months and 75% by 29.6 months. CONCLUSIONS: In adult EoE steroid responders, loss of treatment response is common, and is associated with a steroid dose reduction. Routinely lowering doses for maintenance steroids may provide inferior outcomes.